Navigation Links
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
Date:1/5/2011

RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ -- Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan. 3 in Circulation.(1)  Stroke and systemic embolism and major bleeding episodes within 30 days of the cardioversion were the major outcome measures.  The analysis reported that rates of stroke and systemic embolism and major bleeding were low and comparable to warfarin in cardioverted patients receiving Pradaxa® (dabigatran etexilate mesylate) 150mg capsules,(1) an oral anticoagulant recently approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in patients with NVAF.(2)

In RE-LY, a total of 1,983 cardioversions were performed in 1,270 patients, with similar numbers in each treatment group (647 in the dabigatran 110mg* group, 672 in the PRADAXA 150mg group and 664 in the warfarin group).(1)  Rates of stroke and systemic embolism within 30 days of cardioversion were low and did not differ significantly between treatment arms (0.77%, 0.3% and 0.6%, respectively; dabigatran 110mg vs. warfarin, p=0.71; PRADAXA 150mg vs. warfarin, p=0.45),(1) though the RE-LY trial and this subgroup analysis were not powered to demonstrate statistical significance.  Similarly, major bleeding within 30 days of cardioversion was infrequent and comparable between treatment groups (1.7%, 0.6% and 0.6%, respectively).(1)

"Cardioversion is one treatment option for patients with atrial fibrillation and requires anticoagulation both prior to and following treatment in order to reduce the risk of stroke," said Rangadham Nagarakanti, MD, Louisiana State University School of Medicine.  "It's helpful to know that patients on PRADAXA who underwent cardioversion had low rates of stroke and systemic embolism
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New PLATO Sub-Analysis of CABG Patients Presented at ACC
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
4. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
(Date:8/28/2015)... 28, 2015  With the heroin epidemic in ... Jacksonville -based Lakeview Health drug and ... helping to explain why fentanyl is causing a new ... 50 times more potent than pharmaceutical grade heroin and ... the risk of death skyrockets. "Fentanyl can ...
(Date:8/28/2015)... 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical company ... announced the filing of a registration statement on Form ... relating to a proposed initial public offering of its ... and the price range for the offering have not ... stock under the symbol "CTMX" on the NASDAQ Global ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... presented at 12th Congress of European Hematology ... -- Alexion,Pharmaceuticals, Inc. today announced results from ... (eculizumab) for the,treatment of paroxysmal nocturnal hemoglobinuria ... organized by The European,Hematology Association (EHA) in ...
... over Placebo Larger at One Year than at ... 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the,benefits ... 2 study in mild-to- moderate Alzheimer's,disease were statistically ... Importantly, on every endpoint studied, the benefits,of Dimebon ...
Cached Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6
(Date:8/31/2015)... TX (PRWEB) , ... August 31, 2015 , ... ... EARLIER Awareness campaign, TAKE ACTION. NOT CHANCES. (SM) will be featured on a ... The eye-catching campaign image is designed to inspire and promote earlier awareness of ...
(Date:8/31/2015)... Ann Arbor, Michigan (PRWEB) , ... August 31, ... ... writes standards, and tests and certifies products for the water, food, health sciences ... as complying with NSF/ANSI 61 for their advanced iron filtration media, Pro-OX Manganese ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... ... 30, 2015 , ... ProTrailer Party is a new and exciting set of ... styled and detailed presets, allowing FCPX users to immerse the audience into the party. ... film makers save time while adding professional titles to every project. , ProTrailer Party ...
(Date:8/30/2015)... ... ... Negotiating an FDA Import Hold Crisis:, Strategies for Challenging FDA Findings, **FDAnews ... , US authorities are holding imports more than ever before, particularly at ports that ... an uptick and a new final rule, having a top-notch import compliance program is ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3
... for,Protective Coatings is pleased to announce that the ... of certification credits,for industrial hygienists who pass the ... Refresher (C-5) training courses. ABIH is a non-profit,professional ... of industrial hygiene and is the certifying organization ...
... House Science and Technology Committee for Holding Health IT ... ... IT Now!,Coalition, co-chaired by former Sen. John Breaux and former Rep. Nancy,Johnson, ... session. "It,s time for Congress to act so that our health ...
... ) announced today the final tabulation of votes at its,Annual Meeting ... -- Shareholders voted to adopt the merger agreement with ... to approve the merger agreement. Approval ... vote of a majority of shares voting on this ...
... SEIU United Healthcare,Workers-West and SEIU Local ... stop Tenet Healthcare Corp. from cutting health ... registered nurses,pharmacists, licensed vocational nurses, respiratory care ... Workers represented by the two unions ...
... Ramps ... Million, CHICAGO, Sept. 26 Since its launch in April, more ... and have lost more than three-quarters of a million pounds.,Challenge founder Dr. ... will lead the way to a million pounds lost by the,final stop ...
... tension, ... avoid tissue damage, ANDOVER, Mass., Sept. 26 Smith ... launch of the,KINSA RC 5.5 Suture Anchor, designed to provide secure repair ... of muscles,and tendons that control shoulder motion. Surgeons can repair these ...
Cached Medicine News:Health News:ABIH Approves Certification Credit for SSPC Training Courses 2Health News:Health IT Now! Coalition Calls on Congress to Pass Health Information Technology Legislation This Year 2Health News:Arrow International Announces Annual Meeting Voting Results 2Health News:Unions File Charges Against Tenet Healthcare Corporation 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 2Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 4
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
Medicine Products: